

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)				Complete if Known			
				Application Number	10/505,244		
				Filing Date	January 18, 2005		
				First Named Inventor	Kuwada		
				Group Art Unit	1614		
				Examiner Name	Pagonakis, Anna		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
<b>NON-PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	<b>C1</b>	Hu <i>et al.</i> , "An IκBα Inhibitor Causes Leukemia Cell Death through a p38 MAP Kinase-dependent, NF-κB-Independent Mechanism," <i>Cancer Res</i> 61:6290-6296, 2001					
	<b>C2</b>	Cory <i>et al.</i> , "Implications of the Involvement of the Endoplasmic Reticulum Stress Pathway in Drug-Induced Apoptosis," <i>Anticancer Res</i> 28(2A):681-686, 2008					
	<b>C3</b>	Vega <i>et al.</i> , "Rituximab-Induced Inhibition of YY1 and Bcl-x <sub>L</sub> Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-x <sub>L</sub> in Fas Resistance and Chemoresistance, Respectively," <i>J Immunol</i> 175:2174-2183, 2005					
	<b>C4</b>	Huerta-Yepez <i>et al.</i> , "Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediates apoptosis via inactivation of NF-κB and inhibition of Bcl-x <sub>L</sub> expression," <i>Oncogene</i> 23:4993-5003, 2004					
	<b>C5</b>	Mabuchi <i>et al.</i> , "Inhibition of NF-κB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models," <i>J Biol Chem</i> 279:23477-23485, 2004					
	<b>C6</b>	El-Rayes <i>et al.</i> , "Phase II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer," <i>Cancer Chemother Pharmacol</i> 61:283-289, 2008					
	<b>C7</b>	Becerra <i>et al.</i> , "Increased Toxicity and Lack of Efficacy of Rofecoxib in Combination with Chemotherapy for Treatment of Metastatic Colorectal Cancer: A Phase II Study," <i>Int J Cancer</i> 105:868-872, 2003					
Examiner Signature:				Date Considered:			
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							